Title
Category
Credits
Event date
Cost
- Basic and Translational
$0.00
Factors influencing drug transport at the BBB: A critical determination of the efficacy in brain tumors.
- Basic and Translational
$0.00
Understanding the genomic biochemical and cellular mechanisms underlying brain tumor development by using a variety of evolutionary and pre-clinical models.
- Basic and Translational
$0.00
Learning the characterization of the genomic and molecular landscape of primary untreated gliomas and understanding the major pathways that are altered in most gliomas.
- Basic and Translational
$0.00
Understanding the basic principles of next-generation sequencing and their applications to brain cancer.
- Clinical Neuro-Oncology for the Basic Scientist
$0.00
Overview:Review the evolving definition of high grade gliomaStandard of care management of newly diagnosed IDH WT glioma and grade IV IDH mut astrocytomaManagement o PseudoprogressionStandard of care management for recurrent IDH WT glioma
- Clinical Neuro-Oncology for the Basic Scientist
$0.00
Overview - Neurosurgical oncology techniques for the basic scientist Achieving maximal safe resection for gliomasSaftey + Maximal Resection - Neuro-navigationSaftey - Brain MappingSaftey - Tubular RetractorsMaximal Resection - 5-ALAMaximal Resection - Intraoperative MRISurgical techniques for non-glioma tumorsHow can surgical advances help further basic science?
- Clinical Neuro-Oncology for the Basic Scientist
$0.00
Understanding clinical trial designs and how they can be utilized for the basic scientist.
- Clinical Neuro-Oncology for the Basic Scientist
$0.00
Outline:Basic understanding the evolution of classification of lower grad gliomas and integration of molecular featuresOverview of role for surgery, radiation, and chemotherapy in management of patients with newly diagnosed lower grade gliomasOverview of role for surgery, radiation, and chemotherapy in management of patients with recurrent diagnosed lower grade gliomasDiscussion of challenges and future direction in managing patients with lower grade gliomas